Trial Profile

A prospective, single-arm clinical study assessing the efficacy and safety of anlotinib combined with EGFR-TKIs as maintenance therapy for oligoprogressive advanced or metastatic EGFR mutant Non-small cell lung cancer after EGFR-TKIS therapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Aumolertinib; Gefitinib; Icotinib; Osimertinib
Indications Non-small cell lung cancer
Focus Therapeutic Use

16 Sep 2022 New trial record
09 Aug 2022 Results (N=7) presented at the 2022 World Conference on Lung Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com